Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%.

Prostate cancer (PCa) is one of the most common malignant tumors in men worldwide. While early detection has improved patient outcomes, effective therapies for advanced disease remain limited. Identifying the molecular drivers of PCa growth and metastasis ...

ArteraAI Prostate is now an FDA-regulated software (as a medical device) to estimate long-term outcomes and predict the benefit of hormone therapy for individual patients with localized prostate cancer. The US Food and Drug Administration (FDA) has granted ...

When a team of doctors diagnosed former President Joe Biden with an aggressive form of prostate cancer last month, it cast the most commonly occurring cancer among men into the national spotlight. But for as common as it is, there remain questions, even ...

SAN FRANCISCO — A genomic test can identify patients with recurrent prostate cancer who are most likely to benefit from adding hormone therapy to secondary radiotherapy, according to findings presented at the American Society for Radiation Oncology 2025 ...

Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive prostate cancer. Among patients with with metastatic hormone-sensitive prostate cancer (mHSPC), Nubeqa (darolutamide) and androgen ...

NEW YORK (AP) — Tennis great Björn Borg reveals in the last chapter of his upcoming memoir, Heartbeats, that he was diagnosed with an "extremely aggressive" prostate cancer, and he told The Associated Press that it is in remission after an operation in ...

Please provide your email address to receive an email when new articles are posted on . A genetic test that identifies the PAM50 biomarker predicted which patients with recurrent prostate cancer would benefit from hormone therapy. Patients with luminal B ...